LUCIO DELL'ATTI

Dr. LUCIO DELL'ATTI

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2015 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
CBChiara Borghi
Chiara Borghi
LDLUCIO DELL'ATTI
LUCIO DELL'ATTI

25 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LDLUCIO DELL'ATTI
LUCIO DELL'ATTI
Nicoletta BianchiNicoletta Bianchi
Nicoletta Bianchi
GAGianluca Aguiari
Gianluca Aguiari
Patients suffering from metastatic renal cell carcinoma (mRCC) show an overall survival rate of lower than 10% after 5 years from diagnosis. Currently, the first-line treatment for mRCC patients is based on antiangiogenic drugs that are able to inhibit tyrosine kinase receptors (TKI) in combination with immuno-oncology (IO) therapy or IO-IO treatments. Second-line therapy involves the use of other TKIs, immunotherapeutic drugs, and mTOR inhibitors. Nevertheless, many patients treated with mTOR and TK inhibitors acquire drug resistance, making the therapy ineffective. Therefore, the research of new therapeutic targets is crucial for improving the overall survival and quality of life of mRCC patients. The investigation of the molecular basis of RCC, especially in clear cell renal cell carcinoma (ccRCC), has led to the identification of different signaling pathways that are involved in renal carcinogenesis. Most of ccRCCs are associated with mutation in VHL gene, which mediates the degradation of hypoxia-inducible factors (HIFs), that, in turn, regulate the pathways related to tumorigenesis, including angiogenesis and invasion. Renal tumorigenesis is also associated with the activation of tyrosine kinases that modulate the PI3K-Akt-mTOR pathway, promoting cell proliferation and survival. In ccRCC, the abnormal activity of mTOR activates the MDM2 protein, which leads to the degradation of tumor suppressor p53 via proteasome machinery. In addition, p53 may be degraded by autophagy in a mechanism involving the enzyme transglutaminase 2 (TG2). Suppression of wild-type p53 promotes cell growth, invasion, and drug resistance. Finally, the activation of ferroptosis appears to inhibit cancer progression in RCC. In conclusion, these pathways might represent new therapeutic targets for mRCC.

1 April 2018 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
LDLUCIO DELL'ATTI
LUCIO DELL'ATTI
AGANDREA Benedetto GALOSI
ANDREA Benedetto GALOSI

26 August 2014 in Urologia Journal
Verified
Journal Article
Closed access
LDLUCIO DELL'ATTI
LUCIO DELL'ATTI
Introduction: The aim of this study was to compare the safety and efficacy of silodosin (8 mg) versus tamsulosin (0.4 mg) as a medical expulsive therapy for distal ureteral stones.Methods: 136 patients (aged 18 years or older) had presented with renal colic, were diagnosed to have a single, unilateral, radiopaque, proximal ureteral stone (range 4–10 mm in size), and agreed to undergo conservative management. For a 3-week period, 68 patients per group were assigned to the following treatments: Group A (gA) received tamsulosin 0.4 mg once daily, and Group B (gB) received silodosin 8 mg once daily. The time to expulsion, analgesic use, follow-up, endoscopic treatment and adverse effects of drugs were noted.Results: Considering all the patients enrolled (136), one patient in gA and two patients in gB were unable to continue the study because of orthostatic hypotension within a week from commencing the treatment. A total of 133 patients (gA: 67; gB: 66) were included in this study. A stone expulsion rate of 61.2% (41 out of 67 patients) was observed in gA, and 80.3% (53 out of 66) was observed in gB. gB showed a statistically relevant advantage in terms of stone expulsion rate (p: 0.003), as well as in terms of expulsion time (weeks) (p: 0.002). No severe complications were recorded in both groups. Four patients (10.2%; 4/39) in gA and ten patients (22.7%; 10/44) in gB experienced retrograde ejaculation (<0.002).Conclusion: The patients treated with silodosin showed a significant increase in expulsion rate and a decrease in expulsion time of lower ureteral stones in our study.

1 January 2015 in Urology Annals
Verified
Journal Article
Open access
LDLUCIO DELL'ATTI
LUCIO DELL'ATTI
The aim of this study was to evaluate the combination of intralesional verapamil injection (IVI) therapy with and tadalafil in men affected by Peyronie's disease (PD). In this study, 59 patients diagnosed with PD, were divided into three groups. Group A (GA) counted 23 patients treated with IVI; Group B (GB) treated 19 patients with tadalafil 5 mg once a day, and Group C (GC) treated 17 patients with IVI and tadalafil for 3 months. There were assessed at baseline and follow-up: Erectile function, presence and severity of painful erections, penile plaque size and penile curvature degree. After 3 months pain resolved completely in 57% cases of GA, 61% of GB and 76% of GC; the final mean curvature degree further decreased in all groups without statistically significant differences; mean plaque size remained stable in GA: 1.57 versus 1.59 at baseline (P = 0.364) and GB: 1.51 versus 1.52 at baseline (P = 0,265), while a further decrease was evident in GC: 1.46 versus 1.58 at baseline (P = 0.03). Mean International Index of Erectile Function-5 score further improved significantly in the group treated with verapamil plus tadalafil: 23.1 versus 14.4 of GA and 18.2 of GB (P ≤ 0.01). The association of IVI and tadalafil showed better pain control while reducing penile curvature and erectile function, improving the quality of life.

Verified
Journal Article
Open access
PDF file
RFRocco Francesco Delle Fave
Rocco Francesco Delle Fave
GPGiordano Polisini
Giordano Polisini
GGGianluca Giglioni
Gianluca Giglioni
APArnaldo Parlavecchio
Arnaldo Parlavecchio
LDLUCIO DELL'ATTI
LUCIO DELL'ATTI
AGANDREA Benedetto GALOSI
ANDREA Benedetto GALOSI
Objectives: The aim of this review is to summarize, following a timeline, the current knowledge regarding the effects of the Sars-cov2 virus on male fertility, researching the pathological and clinical results of the studies published in the last year. Methods: A systematic research was performed on the major international online databases; Thirty-five articles were selected. Results: A statistically significant reduction in testosterone levels and sperm quality in subjects with COVID-19 has been highlighted in several papers; however, in many cases the tests have been conducted in patients with active disease and long-term consequences are still not known. Some studies have confirmed the presence of the virus in the testis in a low percentage of patients; viral presence in sperm has only been found in one study. Testicular discomfort, which could indicate viral orchitis, was highlighted in several works, with an incidence of up to 19% percent of patients. The presence of inflammatory lymphocytic infiltrates, IgG and inflammatory cytokines have been documented in several works; pathological signs of inflammation were found in 60.9% of testicular biopsies performed in one study. The entry of the virus into the testis cells, both stromal and seminal cells appeared to be Angiotensin Converting Enzyme-2 (ACE2) mediated, as it also occurs in other tissues. DNA fragmentation, reactive oxygen species (ROS) formation, autoantibody production and ACE2 mediated effect have all been hypothesized as cause of cellular damage. Conclusions: The results on effects of COVID-19 infection on the male reproductive system are currently insufficient as they are based on a small number of patients and therefore are often contradictory.Certain mechanisms of testicular damage are still to be assessed, as any risk categories like age, ethnicity, or others. As for the transmission of the virus through sperm, there is insufficient evidence to ensure that this cannot happen.